Ascendis Pharma Statistics
Total Valuation
Ascendis Pharma has a market cap or net worth of $14.82 billion. The enterprise value is $14.40 billion.
| Market Cap | 14.82B |
| Enterprise Value | 14.40B |
Important Dates
The next estimated earnings date is Wednesday, November 11, 2026, after market close.
| Earnings Date | Nov 11, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
Ascendis Pharma has 65.67 million shares outstanding. The number of shares has increased by 6.52% in one year.
| Current Share Class | 65.67M |
| Shares Outstanding | 65.67M |
| Shares Change (YoY) | +6.52% |
| Shares Change (QoQ) | +5.89% |
| Owned by Insiders (%) | 0.02% |
| Owned by Institutions (%) | 80.08% |
| Float | 65.64M |
Valuation Ratios
The trailing PE ratio is 16.85 and the forward PE ratio is 31.82.
| PE Ratio | 16.85 |
| Forward PE | 31.82 |
| PS Ratio | 12.39 |
| Forward PS | 8.68 |
| PB Ratio | 9.03 |
| P/TBV Ratio | 9.05 |
| P/FCF Ratio | 38.81 |
| P/OCF Ratio | 37.21 |
| PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 47.85, with an EV/FCF ratio of 37.73.
| EV / Earnings | 16.99 |
| EV / Sales | 12.04 |
| EV / EBITDA | 47.85 |
| EV / EBIT | 48.74 |
| EV / FCF | 37.73 |
Financial Position
The company has a current ratio of 2.99, with a Debt / Equity ratio of 0.31.
| Current Ratio | 2.99 |
| Quick Ratio | 2.23 |
| Debt / Equity | 0.31 |
| Debt / EBITDA | 1.63 |
| Debt / FCF | 1.35 |
| Interest Coverage | 2.01 |
Financial Efficiency
Return on equity (ROE) is 118.78% and return on invested capital (ROIC) is 12.98%.
| Return on Equity (ROE) | 118.78% |
| Return on Assets (ROA) | 9.58% |
| Return on Invested Capital (ROIC) | 12.98% |
| Return on Capital Employed (ROCE) | 14.20% |
| Weighted Average Cost of Capital (WACC) | 7.44% |
| Revenue Per Employee | $1.01M |
| Profits Per Employee | $712,727 |
| Employee Count | 1,189 |
| Asset Turnover | 0.62 |
| Inventory Turnover | 0.30 |
Taxes
| Income Tax | -735.66M |
| Effective Tax Rate | n/a |
Stock Price Statistics
| Beta (5Y) | 0.49 |
| 52-Week Price Change | n/a |
| 50-Day Moving Average | 251.33 |
| 200-Day Moving Average | n/a |
| Relative Strength Index (RSI) | 34.85 |
| Average Volume (20 Days) | 864,640 |
Short Selling Information
The latest short interest is 4.20 million, so 7.59% of the outstanding shares have been sold short.
| Short Interest | 4.20M |
| Short Previous Month | 3.69M |
| Short % of Shares Out | 7.59% |
| Short % of Float | n/a |
| Short Ratio (days to cover) | 8.11 |
Income Statement
In the last 12 months, Ascendis Pharma had revenue of $1.20 billion and earned $847.43 million in profits. Earnings per share was $13.38.
| Revenue | 1.20B |
| Gross Profit | 1.09B |
| Operating Income | 295.51M |
| Pretax Income | 111.78M |
| Net Income | 847.43M |
| EBITDA | 300.99M |
| EBIT | 295.51M |
| Earnings Per Share (EPS) | $13.38 |
Balance Sheet
The company has $927.98 million in cash and $514.19 million in debt, with a net cash position of $413.78 million or $6.30 per share.
| Cash & Cash Equivalents | 927.98M |
| Total Debt | 514.19M |
| Net Cash | 413.78M |
| Net Cash Per Share | $6.30 |
| Equity (Book Value) | 1.64B |
| Book Value Per Share | 24.99 |
| Working Capital | 1.06B |
Cash Flow
In the last 12 months, operating cash flow was $398.15 million and capital expenditures -$16.39 million, giving a free cash flow of $381.76 million.
| Operating Cash Flow | 398.15M |
| Capital Expenditures | -16.39M |
| Depreciation & Amortization | 5.46M |
| Net Borrowing | -34.32M |
| Free Cash Flow | 381.76M |
| FCF Per Share | $5.81 |
Margins
Gross margin is 91.30%, with operating and profit margins of 24.70% and 70.84%.
| Gross Margin | 91.30% |
| Operating Margin | 24.70% |
| Pretax Margin | 9.34% |
| Profit Margin | 70.84% |
| EBITDA Margin | 25.16% |
| EBIT Margin | 24.70% |
| FCF Margin | 32.01% |
Dividends & Yields
Ascendis Pharma does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | -6.52% |
| Shareholder Yield | -6.52% |
| Earnings Yield | 5.72% |
| FCF Yield | 2.58% |
Analyst Forecast
The average price target for Ascendis Pharma is $311.56, which is 38.10% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $311.56 |
| Price Target Difference | 38.10% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 20 |
| Revenue Growth Forecast (3Y) | 52.01% |
| EPS Growth Forecast (3Y) | n/a |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | |
| Graham Upside |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
Ascendis Pharma has an Altman Z-Score of 8.97 and a Piotroski F-Score of 7.
| Altman Z-Score | 8.97 |
| Piotroski F-Score | 7 |